Arthur David J. 4
4 · Salarius Pharmaceuticals, Inc. · Filed May 31, 2022
Insider Transaction Report
Form 4
Arthur David J.
DirectorChief Executive Officer
Transactions
- Purchase
Common Stock
2022-05-26$0.18/sh+708$127→ 282,382 total(indirect: By son) - Purchase
Common Stock
2022-05-26$0.18/sh+3,400$612→ 263,074 total - Purchase
Common Stock
2022-05-26$0.18/sh+18,600$3,385→ 281,674 total - Purchase
Common Stock
2022-05-26$0.18/sh+10,392$1,870→ 292,774 total(indirect: By son) - Purchase
Common Stock
2022-05-26$0.18/sh+10,800$1,990→ 303,574 total(indirect: By daughter)
Footnotes (1)
- [F1]The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.